Seeking Alpha

Shares of Aeterna Zentaris (AEZS +13.2%) pop after being initiated with a Buy at Roth Capital...

Shares of Aeterna Zentaris (AEZS +13.2%) pop after being initiated with a Buy at Roth Capital with a price target of $1.75, more than double its current valuation. Roth cites optimism over its endometrial cancer candidate, AEZS-108, which plans to begin Phase III testing before the end of the year, the potential for its AEZS-130, an Adult Growth Hormone Deficiency diagnostic that the company is preparing for a New Drug Application.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|